Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is anticipated to issue its resultson Thursday, November 5th. Analysts expect Carisma Therapeutics to post earnings of ($0.1237) per share and revenue of $4.66 million for the quarter.
Carisma Therapeutics Price Performance
Shares of CARM stock opened at $0.00 on Thursday. The firm has a market capitalization of $20,922.50, a price-to-earnings ratio of 0.00 and a beta of -9.60. Carisma Therapeutics has a twelve month low of $0.00 and a twelve month high of $0.10.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that harness and genetically engineer myeloid cells, including monocytes and macrophages, to treat cancer and other serious diseases. The company’s platform is designed to create engineered immune cells that can recognize disease-associated targets, enter solid tumors and alter the tumor microenvironment.
Carisma’s primary product candidate is CT-0525, an investigational HER2-targeted chimeric antigen receptor (CAR) monocyte therapy being developed for patients with advanced solid tumors.
Recommended Stories
- Five stocks we like better than Carisma Therapeutics
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
